Losing body weight sounds straightforwardly good, but the body does not always shed fat and fat alone. Researchers have grown increasingly interested in what happens to skeletal muscle during rapid weight loss, because muscle does far more than move limbs. It plays a central role in how the body handles blood sugar, generates heat, and sustains everyday mobility.
A study published in the Proceedings of the National Academy of Sciences examined this question directly. The researchers used a mouse model of diet-induced obesity and treated the animals with a long-acting GLP-1 receptor agonist, the class of peptide drug most associated with dramatic weight reduction in recent years. Their findings confirmed a concern that has been surfacing in the clinical literature: meaningful weight loss with this peptide came alongside a notable loss of skeletal muscle mass.
The more intriguing finding, though, was what happened next. When the research team added an inhibitor of an enzyme called 15-hydroxyprostaglandin dehydrogenase, abbreviated 15-PGDH, the muscle loss picture changed considerably, and it did so without undoing the weight loss itself.
GLP-1 receptor agonists and the muscle question
GLP-1 receptor agonists work by mimicking a natural gut hormone called glucagon-like peptide-1. Activating that receptor pathway reduces appetite and slows stomach emptying, which together produce a sustained calorie deficit and, over time, significant weight reduction. The peptide used in this study was semaglutide, a long-acting version of the GLP-1 receptor agonist class.
The study's mouse data showed that semaglutide alone caused significant loss of muscle mass in obese animals. Interestingly, contractile function, meaning the basic ability of the muscle to contract, was preserved even as the tissue itself shrank. That distinction matters because it suggests the problem is not that muscle stops working acutely, but that less of it remains, which could have longer-term implications for metabolic health and physical capacity.
The researchers also introduced a muscle injury to the obese mice to study how well the remaining muscle could repair itself. Here the picture became more complex. Obese mice already showed an abnormal response to injury, developing pathological calcifications in the damaged tissue. These calcium deposits are typically associated with a severe inherited muscle disease called Duchenne Muscular Dystrophy, making their appearance in the obesity model a striking finding.
What semaglutide did to injury and repair
When obese mice with muscle injuries were treated with semaglutide, the peptide had a split effect. On one hand, it reduced the calcific remodeling, meaning fewer abnormal calcium deposits formed in the healing tissue. That looks like a benefit. On the other hand, the newly regenerated muscle fibers that grew back after injury were smaller than expected. Smaller regenerated fibers suggest impaired recovery, because fiber size is directly tied to the force a muscle can produce.
This impaired regenerative growth is important context for anyone following the research literature on GLP-1 receptor agonists. The drug class may help the metabolic environment in one way while simultaneously limiting the repair process that lets muscle rebuild itself after stress. The researchers framed this as a dual effect: beneficial reduction of calcification, but a clear cost to regenerative fiber growth.
The 15-PGDH enzyme and its role in aging tissue
To understand the proposed solution, it helps to know what 15-PGDH does. The enzyme breaks down prostaglandins, which are short-lived signaling molecules involved in inflammation, tissue repair, and cell growth. Prostaglandins are not simply inflammatory nuisances. In muscle, certain prostaglandins appear to support the activity of muscle stem cells, which are the cells responsible for repairing and rebuilding muscle fibers after injury.
The study authors describe 15-PGDH as a gerozyme, a term for an enzyme whose activity increases with aging and injury. When this enzyme is overactive, it degrades prostaglandins faster than the tissue can use them, potentially starving the repair process of necessary signals. Prior research has linked elevated 15-PGDH activity to impaired muscle regeneration in aged animals, making it a plausible target for interventions aimed at preserving muscle quality.
A small-molecule inhibitor of 15-PGDH, referred to in the study as PGDHi, was already available from earlier research. The current study asked whether that inhibitor could compensate for the muscle repair deficit seen with semaglutide treatment.
Combining the two treatments in obese mice
When researchers gave obese mice both semaglutide and the 15-PGDH inhibitor together, the results were notably different from semaglutide alone. The combination stimulated muscle stem cell activity, which in turn drove larger regenerated myofiber sizes after injury. The end result was enhanced muscle strength, measured as actual contractile force output, compared to mice receiving semaglutide without the inhibitor.
Critically, adding the 15-PGDH inhibitor did not compromise the weight loss achieved by semaglutide. The two compounds appeared to work in complementary ways: one driving the metabolic and appetite changes that reduce body weight, the other preserving the cellular machinery needed to rebuild muscle tissue. The authors described this relationship as synergistic.
Muscle force recovery is a meaningful outcome because it goes beyond mass. A muscle can be large but weak, or small but functionally intact. The fact that the combination treatment improved force output, rather than simply increasing fiber size on a microscope slide, gives the result practical significance in understanding how muscle quality might be maintained during weight-loss therapies.
Prostaglandins and muscle stem cell function
The mechanism the researchers propose centers on prostaglandin signaling within muscle stem cells, also called satellite cells. These cells sit dormant alongside muscle fibers and activate in response to injury. Their ability to proliferate, differentiate, and fuse into new fibers determines how completely a muscle recovers.
By inhibiting 15-PGDH, the treatment preserves local prostaglandin concentrations, keeping the signaling environment that muscle stem cells depend on more intact. Early data from this and related work suggests that prostaglandin pathways are not peripheral to the repair process but are central to how stem cells receive and interpret injury signals. When those signals are degraded too quickly, repair proceeds less efficiently.
This framing also helps explain why the enzyme inhibitor had little effect on weight loss. Prostaglandin signaling in muscle tissue is relatively compartmentalized. Preserving it locally does not appear to override the systemic appetite and metabolic effects that GLP-1 receptor agonists produce through brain and gut receptors.
Limitations and what comes next
The study was conducted entirely in mice, which is an important limitation. Mouse muscle biology shares meaningful overlap with human muscle biology, but rodent models of obesity and injury do not reproduce every feature of human disease. The pathological calcifications observed in obese mice, for instance, are not commonly reported in humans undergoing GLP-1 receptor agonist therapy, so some findings may be specific to the model.
The 15-PGDH inhibitor used here is a research compound. It has not been tested in clinical trials in humans, and the study authors do not claim it is ready for therapeutic use. What the research provides is a mechanistic proof of concept: blocking this particular prostaglandin-degrading enzyme can, in a mouse model, rescue the muscle repair deficit associated with GLP-1 receptor agonist treatment.
For researchers studying the intersection of metabolic peptides and musculoskeletal biology, these results open a line of investigation worth following. The question of how to preserve or rebuild muscle during weight loss is increasingly recognized as central to the long-term outcomes of obesity treatment, and a target like 15-PGDH offers a specific, biochemically defined point of intervention for future study.
